Trial Profile
A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Desloratadine (Primary) ; Cetirizine
- Indications Urticaria
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon
- 07 May 2014 New trial record